CL2009000699A1 - Compuestos derivados de 6-heteroaril-imidazo[1,2-a]piridinas polisustituidas; composicion farmaceutica; procedimiento de sintesis; compuestos intermediarios; y su uso para tratar o prevenir enfermedades neurodegenerativas, psiquiatricas, inflamatorias, traumatismos cerebrales y de la epilepsia, osteoporosis, cancer, parkinson, entre otras. - Google Patents

Compuestos derivados de 6-heteroaril-imidazo[1,2-a]piridinas polisustituidas; composicion farmaceutica; procedimiento de sintesis; compuestos intermediarios; y su uso para tratar o prevenir enfermedades neurodegenerativas, psiquiatricas, inflamatorias, traumatismos cerebrales y de la epilepsia, osteoporosis, cancer, parkinson, entre otras.

Info

Publication number
CL2009000699A1
CL2009000699A1 CL2009000699A CL2009000699A CL2009000699A1 CL 2009000699 A1 CL2009000699 A1 CL 2009000699A1 CL 2009000699 A CL2009000699 A CL 2009000699A CL 2009000699 A CL2009000699 A CL 2009000699A CL 2009000699 A1 CL2009000699 A1 CL 2009000699A1
Authority
CL
Chile
Prior art keywords
polysubstituted
pyridines
psychiatric
imidazo
epilepsy
Prior art date
Application number
CL2009000699A
Other languages
English (en)
Spanish (es)
Inventor
Yannick Evanno
David Machnik
Peretti Danielle De
Nathalie Rakotoarisoa
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39764971&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000699(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2009000699A1 publication Critical patent/CL2009000699A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2009000699A 2008-03-21 2009-03-20 Compuestos derivados de 6-heteroaril-imidazo[1,2-a]piridinas polisustituidas; composicion farmaceutica; procedimiento de sintesis; compuestos intermediarios; y su uso para tratar o prevenir enfermedades neurodegenerativas, psiquiatricas, inflamatorias, traumatismos cerebrales y de la epilepsia, osteoporosis, cancer, parkinson, entre otras. CL2009000699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801585A FR2928924B1 (fr) 2008-03-21 2008-03-21 Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
CL2009000699A1 true CL2009000699A1 (es) 2010-04-09

Family

ID=39764971

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000699A CL2009000699A1 (es) 2008-03-21 2009-03-20 Compuestos derivados de 6-heteroaril-imidazo[1,2-a]piridinas polisustituidas; composicion farmaceutica; procedimiento de sintesis; compuestos intermediarios; y su uso para tratar o prevenir enfermedades neurodegenerativas, psiquiatricas, inflamatorias, traumatismos cerebrales y de la epilepsia, osteoporosis, cancer, parkinson, entre otras.

Country Status (24)

Country Link
US (2) US8088765B2 (enExample)
EP (1) EP2262804B1 (enExample)
JP (1) JP5508384B2 (enExample)
KR (1) KR20100124830A (enExample)
CN (2) CN102036989B (enExample)
AR (1) AR070995A1 (enExample)
AU (1) AU2009253232B2 (enExample)
BR (1) BRPI0910309A2 (enExample)
CA (1) CA2719118C (enExample)
CL (1) CL2009000699A1 (enExample)
CO (1) CO6300864A2 (enExample)
EA (1) EA201071111A1 (enExample)
FR (1) FR2928924B1 (enExample)
IL (1) IL208247A0 (enExample)
MA (1) MA32248B1 (enExample)
ME (1) ME01112B (enExample)
MX (1) MX2010010268A (enExample)
NZ (1) NZ588083A (enExample)
PE (1) PE20091694A1 (enExample)
PH (1) PH12012501817A1 (enExample)
TW (1) TW200942541A (enExample)
UY (1) UY31730A (enExample)
WO (1) WO2009144392A1 (enExample)
ZA (1) ZA201006725B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2928922B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
CN102131801B (zh) 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
SI2617420T1 (sl) 2009-05-07 2016-02-29 Forum Pharmaceuticals Inc. Fenoksimetil heterociklične spojine
FR2953520B1 (fr) * 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
TWI429628B (zh) 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
KR101594002B1 (ko) 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Pi3 키나제 억제제로서의 벤즈이미다졸 유도체
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
CN103214481B (zh) * 2012-01-21 2016-08-03 中国科学院上海药物研究所 新型咪唑并[1,2-a]吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
CN106631970A (zh) * 2016-12-14 2017-05-10 贵州大学 一种6‑苯甲酰基‑1h‑吲哚的制备方法
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
CN112752756B (zh) 2018-05-11 2024-06-25 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Pd—1/pd—l1抑制劑之鹽
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド[3,2-d]ピリミジン化合物
EP4058461A1 (en) 2019-11-11 2022-09-21 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
US20230255934A1 (en) * 2020-04-24 2023-08-17 The Regents Of The University Of California Nurr1 receptor modulators and uses thereof
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US20240294529A1 (en) * 2021-07-16 2024-09-05 Sanofi 6h-imidazo[1,2-a]pyrrolo[2,3-e]pyridine derivatives for use in therapy
CN117916240A (zh) 2021-07-16 2024-04-19 赛诺菲 用于疗法的咪唑并[1,2-b][1,2,4]三唑衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476667E (pt) 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
FR2903105A1 (fr) * 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
FR2903107B1 (fr) * 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
US8338437B2 (en) * 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
FR2928922B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2928921B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques

Also Published As

Publication number Publication date
CN103145747B (zh) 2015-06-17
CN102036989A (zh) 2011-04-27
BRPI0910309A2 (pt) 2015-09-29
PE20091694A1 (es) 2009-11-20
MX2010010268A (es) 2011-04-05
EP2262804A1 (fr) 2010-12-22
AU2009253232A1 (en) 2009-12-03
EP2262804B1 (fr) 2014-12-03
JP5508384B2 (ja) 2014-05-28
CO6300864A2 (es) 2011-07-21
CA2719118A1 (fr) 2009-12-03
JP2011515381A (ja) 2011-05-19
MA32248B1 (fr) 2011-04-01
KR20100124830A (ko) 2010-11-29
NZ588083A (en) 2012-07-27
IL208247A0 (en) 2010-12-30
UY31730A (es) 2009-11-10
CN102036989B (zh) 2014-05-07
TW200942541A (en) 2009-10-16
FR2928924A1 (fr) 2009-09-25
US8088765B2 (en) 2012-01-03
ME01112B (me) 2012-12-20
AU2009253232B2 (en) 2013-07-11
US20120053202A1 (en) 2012-03-01
US20110065700A1 (en) 2011-03-17
US8598166B2 (en) 2013-12-03
WO2009144392A1 (fr) 2009-12-03
ZA201006725B (en) 2011-11-30
AR070995A1 (es) 2010-05-19
EA201071111A1 (ru) 2011-08-30
CN103145747A (zh) 2013-06-12
FR2928924B1 (fr) 2010-04-23
CA2719118C (fr) 2016-07-26
PH12012501817A1 (en) 2013-09-02

Similar Documents

Publication Publication Date Title
CL2009000696A1 (es) Compuestos polisustituidos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento y la prevencion de enfermedades neurodegenerativas, de traumatismos cerebrales y epilepsia, enfermedades psiquiatricas, enfermedades inflamatorias, entre otras.
CL2009000695A1 (es) Compuestos derivados de 6-fenil-imidazo[1,2-a]piridina sustituidos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; utiles para el tratamiento y prevencion de enfermedades neurodegenerativas, psiquiatricas, inflamatorias, de traumatismos cerebrales y de la epilepsia, entre otras.
CL2009000697A1 (es) Compuestos derivados de 2-heteroaril-6-fenil-imidazol [1,2-a]piridinas sustituidas; moduladores de receptores not; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de cancer, inflamacion, enfermedades neurodegenerativas, psiquiatricas, epilepsia, entre otras.
EP4480543A3 (en) Chiral diaryl macrocycle and use thereof in the treatment of cancer
CL2012002487A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina, inhibidores de pde10; composicion farmacéutica que los comprende; proceso para preparar la composicion farmaceutica; utiles para el tratamiento de enfermedades neurológicas, psiquiátricas o metabólicas tales como esquizofrenia, parkinson y diabetes, entre otras.
CL2012001714A1 (es) Compuestos derivados de pirrol[3.4-b]piridin-5-ona, inhibidores de pi3k; composicion farmaceutica que los comprende; y uso para el tratamiento de enfermedades tales como alzheimer, epilepsia, esclerosis multiple, parkinson, entre otras.
UA101493C2 (ru) Производные азетидина и циклобутана как ингибиторы jak
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
CL2007003879A1 (es) Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson.
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
WO2006058868A3 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
BRPI0813625A2 (pt) Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
MX2009010407A (es) Derivados fluorados de deferiprona.
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
ECSP088366A (es) 1,2-diarilimidazoles para uso como moduladores de cb1